Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation†
Top Cited Papers
Open Access
- 19 April 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 41 (5) , 1130-1137
- https://doi.org/10.1002/hep.20688
Abstract
Orthotopic liver transplantation (OLT) can be a definitive treatment for patients with hepatocellular carcinoma (HCC). Prolonged waiting times for cadaveric livers, however, may lead to dropout from the waiting list or worsened post‐OLT prognosis as a result of interval tumor progression. Percutaneous radiofrequency ablation (RFA) is widely used for local control of small unresectable HCC, but its pretransplant role remains unclear. We studied the outcome of 52 consecutive patients accepted for OLT bearing 87 HCC nodules and treated with percutaneous RFA. On initial staging, the tumor burden exceeded the Milan criteria in 10 patients. Complete tumor coagulation was observed in 74 of 87 (85.1%) nodules based on postablation imaging. After a mean of 12.7 months (range: 0.3‐43.5) on the waiting list, 3 of 52 patients (5.8%) had dropped out due to tumor progression. Forty‐one patients had undergone transplantation, with 1‐ and 3‐year post‐OLT survival rates of 85% and 76%, respectively. No patient developed HCC recurrence. There were three major complications in 76 RFA procedures (hepatic arterial hemorrhage, small bowel perforation, and liver decompensation salvaged by OLT), without resultant death or dropout. In conclusion, percutaneous RFA is an effective bridge to OLT for patients with compensated liver function and safely accessible tumors. Tumor‐related dropout rate and post‐OLT outcome compared favorably with published controls of patients with early‐stage disease. This can be attributed to the efficacy of RFA in producing local cure or curbing tumor progression during the waiting period. (HEPATOLOGY 2005;41:1130–1137.)Keywords
This publication has 47 references indexed in Scilit:
- Non‐resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention‐to‐treat and dropout from liver transplant waiting listClinical Transplantation, 2004
- Liver transplantation for hepatocellular carcinoma: Further considerations on selection criteriaLiver Transplantation, 2004
- Pre‐transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted liversClinical Transplantation, 2004
- The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinomaHepatology Research, 2004
- Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: Long-term survival in the experience of a single radiologic referral centerLiver Transplantation, 2004
- New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patientsJournal of Surgical Oncology, 2003
- Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: A safe and effective bridge to liver transplantationLiver Transplantation, 2002
- Liver transplantation in association with hepatocellular carcinoma: An update of the international tumor registryLiver Transplantation, 2002
- Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?Journal of Hepatology, 1998
- Liver Transplantation for Hepatocellular CarcinomaAnnals of Surgery, 1998